Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab
- Development stage
- Approved
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Trastuzumab is a humanized monoclonal antibody that targets the extracellular domain of the human epidermal growth factor receptor 2 (HER2). It is primarily used to treat HER2-positive breast cancer and also approved for HER2-positive gastric and gastroesophageal junction cancers. Trastuzumab binds with high affinity to HER2 on tumor cells that overexpress this protein (about 20–30% of breast cancers), inhibiting cell proliferation and survival. Its mechanisms include direct inhibition of HER2-mediated signaling pathways and mediation of antibody-dependent cellular cytotoxicity. The drug was originally developed by Genentech/Roche[1][3][7].
- Brand names
- HerceptinHerceptin HylectaHerzumaKanjintiOntruzantPhesgoTrazimeraOgivriHercessi
- Other names
- 曲妥珠单抗
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab.